Jefferies starts Nuvalent at buy, cites lung cancer drug candidates [Seeking Alpha]
Nuvalent, Inc. (NASDAQ: NUVL) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $97.00 price target on the stock.
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at Leerink Partnrs from a "market perform" rating to an "outperform" rating.
Nuvalent, Inc. (NASDAQ: NUVL) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $69.00.